The CJC-1295 No DAC & Ipamorelin blend combines a tetrasubstituted Growth Hormone Releasing Hormone (GHRH) receptor agonist (Modified GRF 1-29) with a highly selective pentapeptide Growth Hormone Secretagogue Receptor (GHS-R1a) agonist. By simultaneously activating Gs-coupled adenylate cyclase/cAMP and Gq/11-coupled intracellular calcium (Ca2+) cascades in anterior pituitary somatotropes, the CJC/IPA blend generates synergistic, pulsatile growth hormone secretion without stimulating baseline ACTH, cortisol, or prolactin release.
Price range: $65.00 through $119.00
| Quantity | Discounted Price |
|---|---|
| 3 - 5 | $62.40 |
| 7 - 10 | $61.10 |
| 9 + | $59.80 |
The CJC-1295 No DAC & Ipamorelin dual reference complex (commonly designated as CJC 1295 ipamorelin, CJC-1295/ipamorelin, CJC/IPA, or IPA/CJC) is a precision-formulated peptide combination engineered to investigate dual-receptor somatotropic axis activation. The combination pairs CJC-1295 No DAC (also known as Modified GRF 1-29), a 29-amino-acid synthetic analogue of endogenous Growth Hormone Releasing Hormone (GHRH), with Ipamorelin, a selective pentapeptide growth hormone secretagogue.
When evaluated independently, each peptide targets a distinct, complementary receptor class on pituitary somatotropes. When studied in combination, the CJC 1295 peptide complex produces a pronounced synergistic response, elevating growth hormone synthesis and secretion significantly beyond the calculated additive output of either compound alone, while maintaining complete receptor selectivity.
Batch-verified for high analytical purity at Modern Aminos, the CJC-1295 No DAC & Ipamorelin blend is offered in two standardized laboratory formats:
Laboratories researching pituitary secretagogue kinetics, intracellular signal amplification, and neuro-endocrine feedback loops evaluate this blend alongside complementary secretagogues available on the site, such as Tesamorelin, Sermorelin, GHRP-2, and GHRP-6.
| Compound Complex | CJC-1295 No DAC (Modified GRF 1-29) + Ipamorelin Blend |
|---|---|
| Quantity / Formats Offered | 5MG/5MG Lyophilized Powder Vials | 10MG/10MG Lyophilized Powder Vials |
| CJC-1295 No DAC Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Ipamorelin Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Numbers | 863288-34-0 (CJC-1295 No DAC) | 170851-70-4 (Ipamorelin) |
| Chemical Formulas | C152H252N44O42 (CJC-1295) | C38H49N9O5 (Ipamorelin) |
| Molecular Weights | 3367.20 g/mol (CJC-1295 No DAC) | 711.86 g/mol (Ipamorelin) |
| IUPAC Name (CJC-1295 No DAC) | Modified Growth Hormone Releasing Factor (1-29) amide |
| InChIKey (Ipamorelin) | InChIKey=HUPFGBLSBRKMLB-UHFFFAOYSA-N |
The biochemical pathways and cellular targets of the CJC-1295 ipamorelin complex in laboratory research include:
When evaluating research efficacy and published scientific literature for CJC 1295 ipamorelin reference materials:
To evaluate receptor crosstalk, signal transduction kinetics, and secretagogue potency, researchers compare the CJC-1295 No DAC & Ipamorelin complex against standalone reference peptides available at Modern Aminos:
| Compound / Reference | Primary Receptor Target | Core Mechanism of Action | Research Focus & Profile |
|---|---|---|---|
| CJC-1295 No DAC & Ipamorelin Blend | Dual GHRH Receptor & GHS-R1a Agonist | Simultaneously activates Gs/cAMP and Gq/11/Ca2+ pathways, producing synergistic GH pulse amplification | Focuses on dual-pathway somatotrope synergy, physiological GH pulse modeling, and maximal secretagogue receptor cross-talk |
| CJC-1295 No DAC (Mod GRF 1-29) | GHRH Receptor (Gs-Coupled) | Stimulates adenylate cyclase to elevate cAMP and PKA, priming GH gene transcription and vesicle synthesis | Focuses on isolated GHRH receptor kinetics, enzymatic resistance against DPP-IV, and baseline GH transcription research |
| Ipamorelin | GHS-R1a Ghrelin Receptor (Gq/11-Coupled) | Triggers Phospholipase C (PLC) to mobilize cytosolic Ca2+, driving exocytosis of stored GH granules | Focuses on highly selective ghrelin receptor agonism without off-target cortisol, ACTH, or prolactin elevation |
| Tesamorelin | N-Terminal Trans-3-Hexenooyl GHRH Analogue | Binds GHRH receptors with high stability, modulating hepatic IGF-1 transcription and lipid metabolism | Focuses on high-affinity GHRH receptor signaling, hepatic gene expression, and visceral lipid metabolic modeling |
Yes, Modern Aminos is a highly trusted vendor for high-purity research chemicals and reference peptides. Every batch of CJC-1295 No DAC & Ipamorelin undergoes strict third-party analytical testing (including HPLC and Mass Spectrometry) to verify minimum 98%+ purity for both active peptide sequences, correct amino acid composition, and complete absence of heavy metals or synthesis impurities.
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) lysine linker. Without DAC, it produces natural, rapid-onset, pulsatile GHRH receptor stimulation matching physiological GH pulses. CJC-1295 with DAC binds serum albumin to create continuous, non-pulsatile receptor activation.
CJC-1295 No DAC activates the Gs/cAMP pathway to prime growth hormone transcription and storage, while Ipamorelin activates the Gq/11/Ca2+ pathway to trigger granule release. Activating both intracellular cascades simultaneously produces a synergistic GH release greater than the sum of either peptide alone.
Preclinical research demonstrates that Ipamorelin is exceptionally selective for GHS-R1a. Unlike older secretagogues (such as GHRP-2 or GHRP-6), Ipamorelin does not trigger off-target ACTH, cortisol, prolactin, or aldosterone release in pituitary cell culture models.
Modern Aminos provides the CJC-1295 No DAC & Ipamorelin complex in two standardized dual-vial reference sizes: a 5MG/5MG lyophilized powder complex and a high-density 10MG/10MG lyophilized powder complex.
Modern Aminos utilizes High-Performance Liquid Chromatography (HPLC) to confirm active purity exceeding 98% for both components and Mass Spectrometry (MS) to verify the exact molecular weights (3367.20 g/mol for CJC-1295 No DAC; 711.86 g/mol for Ipamorelin).
This reference complex is primarily evaluated in somatotrope cell culture assays to study GHRH/GHS-R1a receptor co-localization, intracellular cAMP and Ca2+ second-messenger crosstalk, and pulsatile growth hormone secretion dynamics.
Unopened lyophilized CJC-1295 No DAC & Ipamorelin vials should be stored frozen at -20°C for long-term preservation. Protect from direct light exposure, elevated temperatures, and atmospheric moisture to maintain solid-state peptide stability.
Disclaimer: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.
By purchasing this product, you confirm that:
Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.
